Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Metastatic Uveal Melanoma
- Main trialPhase 1/2
- “This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.”In the company’s words, NCT05415072 on ClinicalTrials.gov
Other drugs for Metastatic Uveal Melanoma
- DarovasertibIDEAYA Biosciences · Phase 3
- AU-011Aura Biosciences · Phase 3
- RP2Replimune, Inc. · Phase 2/3
- Melphalan/HDSDelcath Systems Inc. · Phase 3
- EB-DTKN-401Beijing Biotech · Phase 1/2
- RoginolisibiOnctura · Phase 2
Coming up1
- 1 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 1 Oct 2027 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026